Glycemic management in patients with immune-related diabetes mellitus: A scoping review
Immune checkpoint inhibitors therapy in cancer patients may induce immune-related diabetes mellitus through islet β-cell destruction, necessitating systematic glycemic management. This scoping review aims to identify and synthesize evidence on glycemic management strategies for immune-related diabet...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | SAGE Open Medicine |
| Online Access: | https://doi.org/10.1177/20503121251358313 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849254239766839296 |
|---|---|
| author | Yuan Jiang Xiaoyan Wang Lei Lei Lihua Liu Danfeng Wu Siqi Zhang Dairong Tang Lingli Fan Zhou Wen Xiaojing Xue Gang Feng |
| author_facet | Yuan Jiang Xiaoyan Wang Lei Lei Lihua Liu Danfeng Wu Siqi Zhang Dairong Tang Lingli Fan Zhou Wen Xiaojing Xue Gang Feng |
| author_sort | Yuan Jiang |
| collection | DOAJ |
| description | Immune checkpoint inhibitors therapy in cancer patients may induce immune-related diabetes mellitus through islet β-cell destruction, necessitating systematic glycemic management. This scoping review aims to identify and synthesize evidence on glycemic management strategies for immune-related diabetes mellitus. Guided by Arksey and O’Malley’s five-stage scoping review framework, we strictly adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. A systematic search was conducted across guideline repositories, academic databases, and professional oncology/endocrinology association websites. The search period spanned from database inception to June 30, 2024. Of 5085 initially identified records, 9 studies met inclusion criteria. Evidence was synthesized into five key domains: (1) risk assessment and early detection, (2) therapeutic interventions and monitoring, (3) patient education, (4) glycemic target optimization, and (5) multidisciplinary care coordination. This review consolidates evidence-based best practices for immune-related diabetes mellitus management derived from rigorous methodology. Clinicians should tailor these strategies to individual patient profiles to optimize outcomes while mitigating treatment disruptions. |
| format | Article |
| id | doaj-art-64ac499e07124f0e9c6498ef444cf045 |
| institution | Kabale University |
| issn | 2050-3121 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medicine |
| spelling | doaj-art-64ac499e07124f0e9c6498ef444cf0452025-08-20T03:56:05ZengSAGE PublishingSAGE Open Medicine2050-31212025-07-011310.1177/20503121251358313Glycemic management in patients with immune-related diabetes mellitus: A scoping reviewYuan Jiang0Xiaoyan Wang1Lei Lei2Lihua Liu3Danfeng Wu4Siqi Zhang5Dairong Tang6Lingli Fan7Zhou Wen8Xiaojing Xue9Gang Feng10Department of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaState Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Yuzhong District, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaDepartment of Oncology, Mianyang Central Hospital, Sichuan Province, ChinaImmune checkpoint inhibitors therapy in cancer patients may induce immune-related diabetes mellitus through islet β-cell destruction, necessitating systematic glycemic management. This scoping review aims to identify and synthesize evidence on glycemic management strategies for immune-related diabetes mellitus. Guided by Arksey and O’Malley’s five-stage scoping review framework, we strictly adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. A systematic search was conducted across guideline repositories, academic databases, and professional oncology/endocrinology association websites. The search period spanned from database inception to June 30, 2024. Of 5085 initially identified records, 9 studies met inclusion criteria. Evidence was synthesized into five key domains: (1) risk assessment and early detection, (2) therapeutic interventions and monitoring, (3) patient education, (4) glycemic target optimization, and (5) multidisciplinary care coordination. This review consolidates evidence-based best practices for immune-related diabetes mellitus management derived from rigorous methodology. Clinicians should tailor these strategies to individual patient profiles to optimize outcomes while mitigating treatment disruptions.https://doi.org/10.1177/20503121251358313 |
| spellingShingle | Yuan Jiang Xiaoyan Wang Lei Lei Lihua Liu Danfeng Wu Siqi Zhang Dairong Tang Lingli Fan Zhou Wen Xiaojing Xue Gang Feng Glycemic management in patients with immune-related diabetes mellitus: A scoping review SAGE Open Medicine |
| title | Glycemic management in patients with immune-related diabetes mellitus: A scoping review |
| title_full | Glycemic management in patients with immune-related diabetes mellitus: A scoping review |
| title_fullStr | Glycemic management in patients with immune-related diabetes mellitus: A scoping review |
| title_full_unstemmed | Glycemic management in patients with immune-related diabetes mellitus: A scoping review |
| title_short | Glycemic management in patients with immune-related diabetes mellitus: A scoping review |
| title_sort | glycemic management in patients with immune related diabetes mellitus a scoping review |
| url | https://doi.org/10.1177/20503121251358313 |
| work_keys_str_mv | AT yuanjiang glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT xiaoyanwang glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT leilei glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT lihualiu glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT danfengwu glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT siqizhang glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT dairongtang glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT linglifan glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT zhouwen glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT xiaojingxue glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview AT gangfeng glycemicmanagementinpatientswithimmunerelateddiabetesmellitusascopingreview |